Seres Therapeutics Inc (NASDAQ:MCRB) has a beta value of 2.24 and has seen 3.91 million shares traded in the last trading session. The company, currently valued at $124.58M, closed the last trade at $0.82 per share which meant it gained $0.08 on the day or 11.08% during that session. The MCRB stock price is -710.98% off its 52-week high price of $6.65 and 34.15% above the 52-week low of $0.54. The 3-month trading volume is 4.08 million shares.
Seres Therapeutics Inc (NASDAQ:MCRB) trade information
Sporting 11.08% in the green in last session, the stock has traded in the green over the last five days, when the MCRB stock price touched $0.82 or saw a rise of 1.19%. Year-to-date, Seres Therapeutics Inc shares have moved -41.07%, while the 5-day performance has seen it change 47.35%. Over the past 30 days, the shares of Seres Therapeutics Inc (NASDAQ:MCRB) have changed 5.74%.
Seres Therapeutics Inc (MCRB) estimates and forecasts
Figures show that Seres Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -40.00% over the past 6 months, with this year growth rate of -29.21%, compared to 12.90% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 40.40% and -186.10% for the next quarter. Revenue growth from the last financial year stood is estimated to be -98.90%.
6 analysts offering their estimates for the company have set an average revenue estimate of $250k for the current quarter. 6 have an estimated revenue figure of $250k for the next quarter concluding in Jun 2024. Year-ago sales stood $1.38 million and $126.47 million respectively for this quarter and the next, and analysts expect sales will shrink by -81.90% for the current quarter and -99.80% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 18.22% over the past 5 years.
MCRB Dividends
Seres Therapeutics Inc is expected to release its next earnings report in May this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
